Clinical Trial Update: Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating tolerability and efficacy of the UV1 vaccine in patients with recurrent or metastatic head and neck squamous cell carcinoma planned f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• UV1 vaccine (UV1 vaccine)

Snippet

Sponsor: Martin-Luther-Universität Halle-Wittenberg | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN